Subject Index

Adaptive optics scanning laser ophthalmoscopy (AOSLO)
age-related macular degeneration 14, 19, 20retinal structure imaging 64–66

Advanced Therapy Medicinal Products (ATMPs)
definitions 193, 194distribution 198, 199donor screening and testing 194–196packaging and labeling 198regulatory issues 191, 192

Age-related macular degeneration (AMD)

Best diseaseclinical features 47electro-oculogram 59, 60imaging 47Bone morphogenetic protein 4 (BMP4), retina development role 98Bovine corneal endothelial cell extracellular matrix (BCE-ECM), retinal pigment epithelium explant treatment 134, 135, 137–140
Brn3b, retinal ganglion cell development role 115
Bruch’s membrane
age-related macular degeneration changes and imaging 15, 155, 156
biochemical restoration of aged membranes 133–140
microdevices for age-related macular degeneration implantation 162–164
mesh-supported submicron parylene-C membranes 159, 160, 162–165
micro-electro-mechanical system 157
parylene-C membrane permeability 157–159
perfusion cell viability tests 160, 161 prospects 164, 165
retinal pigment epithelial cell culture and evaluation 161, 162

Cancer-associated retinopathy (CAR),
electroretinogram 57
Cell therapy, see Advanced Therapy Medicinal Products;
Good Manufacturing Practice; Human cell-based medicinal products; specific cells and tissues
Ciliary neurotrophic factor (CNTF)
capsulated cell technology 174 therapeutic prospects 73, 75
Congenital stationary night blindness (CSNB)
electro-oculogram 59
electroretinogram 57
gene correction through cell grafts 168
CRX, expression in retina culture 101–106
Cyclic GMP (cGMP), phototransduction cascade 35–38
Cytomegalovirus (CMV), donor screening and testing 195
Doyne honeycomb dystrophy 49, 50

Electro-oculogram (EOG), applications 58–60
Electroretinogram (ERG)
full-field electroretinogram applications 54–58
multifocal electroretinogram 58
Embryoid body (EB)
retina culture 101, 103, 104
retinal ganglion cell culture 117, 118
retinal pigment epithelium culture 86, 87
Embryonic stem cell (ESC)
encapsulation 113
ethics 112
immunogenicity 123, 124
retina culture 101–104
retinal ganglion cell culture 116–118
retinal pigment epithelium growth 84–86, 89
Encapsulated cell technology (ECT), protein therapy for genetic disease 174, 175
Epstein-Barr virus (EBV), donor screening and testing 195
European Medicines Agency (EMA), cell-based therapy regulation 191, 192
Extracellular matrix, see Bovine corneal endothelial cell extracellular matrix
Fibroblast growth factor (FGF), retina development role 99
Flavin adenine dinucleotide (FAD), age-related macular degeneration fluorescence imaging 11, 12
Fluorescein angiography (FA)
age-related macular degeneration 5, 13, 17, 22, 23
retinal structure imaging 60, 61
retinitis pigmentosa 48
Stargardt disease 45, 46
Food and Drug Administration (FDA), cell-based therapy regulation 191, 192
Fundus autofluorescence (FAF)
age-related macular degeneration 22, 23
retinal structure imaging 61–65
Stargardt disease 46, 61

Gene therapy, sequential gene and cell therapy 173, 174
Geographic atrophy (GA)
age-related macular degeneration 2, 4, 10, 11, 22–24
encapsulated cell technology 174, 175
Glaucoma
retinal ganglion cell loss 111, 113
risk factors 111
Good Manufacturing Practice (GMP)
equipment 183, 184
facilities 184–186
materials and reagents 182, 183
overview for biologics 179, 180
personnel 180, 181
procedures for tissue culture 181, 182
quality assurance 179–182
quality control 179–182
quality management system 199
regulatory issues 189, 190
scale-up methods 186, 187
standard operating procedures 179–181
GRK1, phototransduction cascade 37, 38
Gyrate atrophy, ornithine aminotransferase mutations 106, 169, 172

HEPA filter, Good Manufacturing Practice facilities 184, 185
Hepatitis B, donor screening and testing 195
HLA matching, transplanted stem cells 124, 125
HTLV, donor screening and testing 195
Human cell-based medicinal products (CBMPs) distribution 198, 199
processing and storage 197, 198
procurement 196, 197
traceability 199
Human immunodeficiency virus (HIV), donor screening and testing 195
Human-derived cells and tissues and cellular and tissues-based processes (HCT/Ps) definitions 193
distribution 198, 199
donor screening and testing 194–196
packaging and labeling 198
regulatory issues 191

Immune response
immunomodulation by stem cells 129, 130
neural retina from pluripotent stem cells 107, 108
stem cell immunogenicity
  immune privilege of eye 127–129
  minimization
    HLA matching 124, 125
    immunosuppressants 126
tolerance induction 126, 127
  stem cell types and immune response 123, 124
Immunosuppressants, transplanted stem cells 126
Indocyanine green angiography
age-related macular degeneration 13
retinal structure imaging 60, 61
Induced pluripotent stem cell (iPSC)
derivation 112, 113
disease modeling 106
gene correction with autologous cells 172, 173
homologous recombination to correct gene defects 169
immunogenicity 124
neural retina culture 72, 102, 103, 107
retinal ganglion cell culture 116, 117
retinal pigment epithelium culture 84–86, 89
fate 72–74
Installation qualification (IQ), equipment 183

Lampalizumab, age-related macular degeneration management 11
Lipofuscin, age-related macular degeneration fluorescence imaging 12, 13
Macular degeneration, see Age-related macular degeneration; Best disease; Stargardt disease
Maternally inherited diabetes and deafness (MIDD) 50
Math5, retinal ganglion cell development role 114, 115
Melanin, age-related macular degeneration imaging 13
Melanoma-associated retinopathy (MAR), electroretinogram 57
Mesenchymal stem cell (MSC)
cytokine secretion 129
HLA matching 125
immunogenicity 123
therapeutic prospects 76, 77
Mesh-supported submicron parylene-C membranes (MSPM), age-related macular degeneration microdevices 159, 160, 162–165
Micro-electro-mechanical system (MEMS), age-related macular degeneration microdevices 157
Microperimetry, visual function assessment 53, 54
Near-infrared autoreflectance (NIA), age-related macular degeneration 14, 15, 19, 22–24
Neural stem cell (NSC), therapeutic prospects 75, 76
Neurod1, retinal ganglion cell development role 115
NIPAAm, see Scaffolds
North Carolina macular dystrophy 49
Notch, retina development role 99
Operational qualification (OQ), equipment 183
Optical coherence tomography (OCT)
  age-related macular degeneration 2, 13, 14, 16–18, 22–24
  Best disease 47
  retinal structure imaging 63, 64, 66

Ornithine aminotransferase (OAT)
  gyrate atrophy mutations 106, 169, 172
  homologous recombination to correct gene defects 169

Parylene-C membrane, microdevices for age-related macular degeneration
  mesh-supported submicron parylene-C membranes 159, 160, 162–165
  permeability 157–159

Performance qualification (PQ), equipment 183

Phosphodiesterase-6 (PDE6)
  null allele mouse 40, 41, 174
  phototransduction cascade 36, 38

Photoreceptor cell
  overview 34, 35
  phototransduction cascade 35–38

Protein kinase C (PKC), phototransduction role 38

Quality assurance, see Good Manufacturing Practice

Quality control, see Good Manufacturing Practice

Regulatory issues, cell-based therapy 189–199

Retina
  cell therapy
    immunological considerations 107, 108
    prospects 106, 107
  growth of neural retina from pluripotent stem cells 101–105
  histogenesis and anatomy 98, 99
  transplantation strategies 99, 100

Retinal ganglion cell (RGC)
  development 114, 115
  embryonic stem cell culture 116
  loss in glaucoma 111, 113
  overview 114

Retinal pigment epithelium (RPE)
  biochemical restoration of aged Bruch's membranes 133–140
  cell culture and evaluation for mesh-supported submicron parylene-C membrane microdevices 161, 162
  development 72–74
  growth from pluripotent stem cells
  clinical trials 91, 98
  continuous adherent culture 85, 86
  directed differentiation 87
  embryoid body 86, 87
  stem cell types 84, 85, 87–89
  transplantation strategies 89–91
  overview 34
  scaffolds for transplantation 90, 144–151
  stem cells 74, 75

Retinal progenitor cell (RPC)
  differentiation 72
  injection 145
  scaffolds for transplantation 144–151
  therapeutic prospects 75

Retinal stem cell (RSC), therapeutic prospects 75

Retinitis pigmentosa (RP)
  electroretinogram 57
  fundus autofluorescence 62
  gene mutations 48, 49, 97, 98
  imaging 48
  retinal degeneration 38–41
  stages 39, 40

RHO, phototransduction cascade 35, 36

Scaffolds
  artificial Bruch's membranes 156, 157
  functional overview 144
  materials and fabrication 145, 146
  poly(glycerol-sebacate) 149, 150
  polycaprolactone 149
  retinal pigment epithelium culture transplantation 90, 144–151
  retinal progenitor cell transplantation 144–151
  Sorsby macular dystrophy 50

Standard operating procedures, see Good Manufacturing Practice

Stargardt disease (STGD)
  epidemiology 45
  gene correction through cell grafts 170, 171
  gene mutations 45, 87, 170, 171
  imaging 45, 46
  stages 45

Stem cell, see also specific cells and tissues
  neural retinal fate 71, 72
  overview of types 71
  retinal pigment epithelium fate 72–74
  stem cells 74, 75
  sequential gene and cell therapy 173, 174
<table>
<thead>
<tr>
<th>Subject</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tolerance, induction for transplanted stem cells</td>
<td>126,</td>
</tr>
<tr>
<td></td>
<td>127</td>
</tr>
<tr>
<td>Trypanosoma cruzi, donor screening and testing</td>
<td>195</td>
</tr>
<tr>
<td>Unfolded protein response (UPR), retinal degeneration</td>
<td>40</td>
</tr>
<tr>
<td>Vascular endothelial growth factor (VEGF),</td>
<td></td>
</tr>
<tr>
<td>age-related macular degeneration therapeutic targeting</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10</td>
</tr>
<tr>
<td>X-linked retinoschistis (XLRD)</td>
<td>50</td>
</tr>
</tbody>
</table>